Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement
Rhea-AI Summary
Moolec Science (NASDAQ:MLEC) said Nasdaq Staff issued a memo recommending the Nasdaq Hearings Panel grant an exception through June 29, 2026 to regain compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1), subject to disclosure conditions. The memo cites material balance-sheet improvement after Q4 2025 derecognition events.
Moolec recorded derecognition gains of approximately $91.0M, $5.2M, and $4.6M tied to loss of control of subsidiaries in December 2025 and says these items, plus intercompany liability recognition and a preference-to-ordinary conversion, substantially increased stockholders' equity.
Positive
- Nasdaq Staff supports exception through June 29, 2026
- Derecognition gains totaling approximately $100.8M
- Company reports a substantial increase in stockholders' equity
- Conversion of preference shares into ordinary shares improved equity
Negative
- Loss of control due to December 2025 bankruptcy proceedings
- Reliance on a time-limited Panel exception to remain listed
- Recognition of intercompany liabilities may change future cash flexibility
News Market Reaction
On the day this news was published, MLEC gained 10.62%, reflecting a significant positive market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -9.3% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $558K to the company's valuation, bringing the market cap to $6M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MLEC gained 10.62% while peers were mixed: PRTG -10.39%, NXTC -5.02%, COCP -0.95%, CARM +0.49%, NERV +0.25%. Movements diverge from a broad sector trend, pointing to company-specific drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Nasdaq exception granted | Positive | +4.6% | Nasdaq panel granted exception to regain stockholders’ equity compliance through June 2026. |
| Jan 05 | Share consolidation effective | Neutral | +3.9% | 15-for-1 share consolidation became effective to support Nasdaq listing compliance. |
| Dec 31 | Non-compliance letter | Negative | -4.2% | Nasdaq letter citing failure to meet minimum stockholders’ equity under Rule 5550(b)(1). |
| Dec 31 | Planned share consolidation | Neutral | -4.2% | Announcement of upcoming 15-for-1 share consolidation targeting minimum bid-price compliance. |
| Dec 11 | GLASO campaign update | Positive | -6.7% | Record GLASO safflower campaign with strong yields and acreage expansion in 2025. |
Recent listing-compliance and capital-structure news often moved the stock meaningfully, with both positive and negative reactions, while an operational milestone drew a negative response despite constructive fundamentals.
Over the past several months, Moolec’s news flow centered on Nasdaq listing compliance and capital structure. A 15-for-1 share consolidation on January 5, 2026 aimed to address minimum bid-price requirements, while prior notices in November and December 2025 highlighted bid-price and stockholders’ equity deficiencies. Separately, Moolec showcased operational progress with its GLASO safflower campaign on December 11, 2025. Today’s announcement reinforces that earlier strategy by emphasizing improved stockholders’ equity and a Nasdaq-supported pathway to sustained compliance.
Market Pulse Summary
The stock surged +10.6% in the session following this news. A strong positive reaction aligns with the market’s focus on Moolec’s listing status. The memo supporting an exception through June 29, 2026 and highlighting gains of $91.0 million, $5.2 million, and $4.6 million from derecognition improved stockholders’ equity. Historically, Nasdaq-compliance updates have often moved the stock, though prior reactions to operational news were less supportive, underscoring ongoing volatility risk.
Key Terms
nasdaq hearings panel regulatory
bankruptcy proceedings regulatory
derecognition financial
AI-generated analysis. Not financial advice.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 23, 2026 / Moolec Science S.A. ("Moolec" or the "Company") today announced that Nasdaq Staff has issued a memorandum to the Nasdaq Hearings Panel (the "Panel") concluding that there is sufficient basis to grant Moolec an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions.
The Staff memo reflects Nasdaq's acknowledgment of the material improvement in Moolec's balance sheet following a series of accounting and corporate events completed during the fourth quarter of 2025, which the Company believes have restored compliance with the Stockholders´ Equity Requirement.
During December 2025, bankruptcy proceedings involving certain subsidiaries resulted in the transfer of decision-making authority and the Company's loss of control over those entities. In accordance with IFRS 10.25, the loss of control constituted derecognition events, requiring the removal of the subsidiaries from Moolec's consolidated financial statements.
Specifically, on December 26, 2025, Bioceres S.A. commenced bankruptcy proceedings, resulting in Moolec's loss of control over Bioceres S.A. and its wholly owned subsidiary, Bioceres LLC. These derecognition events have resulted in a gain of approximately
In addition, on December 31, 2025, Theo I SCSp commenced bankruptcy proceedings, resulting in Moolec's loss of control over that entity and a further derecognition gain of approximately
The foregoing derecognition events, together with the recognition of intercompany liabilities arising from the loss of control, which were previously eliminated in consolidation, as well as the conversion of certain preference into ordinary shares, have resulted in a substantial increase in Moolec's stockholders' equity.
Based on these developments, the Company believes it has regained compliance with the Stockholders' Equity Requirement. If the Panel grants an exception, Moolec intends to fully satisfy the conditions outlined in the Staff memo and any related Panel requests. Moolec remains focused on maintaining compliance with Nasdaq's continued listing standards while advancing its strategic priorities and strengthening its financial foundation.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward-looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact: ir@moolecscience.com (phone: +5493412034927)
SOURCE: Moolec Science
View the original press release on ACCESS Newswire
FAQ
What did Moolec (MLEC) announce about Nasdaq compliance on January 23, 2026?
How much did Moolec recognize from derecognition gains in December 2025?
Why did Moolec record derecognition gains in Q4 2025?
Does the Nasdaq exception guarantee continued listing for MLEC after June 29, 2026?
What corporate actions contributed to Moolec's restored equity position for MLEC?
